drugset / Trial / NCT06126406
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Phase 1
Recruiting
60 enrolled
Chongqing Precision Biotech Co., Ltd
First Affiliated Hospital of Wannan Medical College · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CART cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Timeline
- Start
- 2023-11-06
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEA-targeted CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CEA-targeted CAR-T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | CEA-targeted CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |